Results 91 to 100 of about 46,119 (273)

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

The association between white blood cell count and relative risk of non-small cell lung cancer

Discover Oncology
Background High abundance of eosinophils has been proved to associated with favorable disease progression in non-small cell lung cancer (NSCLC) in the previous observational studies, but the causal relationship remains unclear. It is also unclear whether
Xiao Yang, Wenyi Liu, Jiaqi Wang, Weifeng Xia, Lanxiang Wu   +4 more
doaj   +1 more source

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Expert Opinion on Drug Metabolism & Toxicology, 2018
Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This
Nihal El Rouby, J. Lima, Julie A. Johnson   +2 more
semanticscholar   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

The pharmacogenetics of metformin [PDF]

Diabetologia, 2017
Despite its widespread use as the first-line agent for the treatment of type 2 diabetes, it has become clear that metformin does not work optimally for everyone. Elucidating who are the likely metformin responders and non-responders is hampered by our limited knowledge of its precise molecular mechanism of action.
openaire   +2 more sources

Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development

BioTechniques, 2005
Pharmacogenetics and pharmacogenomics are keys to the success of personalized medicine, prescribing drugs based on a patien's individual genetic and biological profile.
Li Yan, Robert A. Beckman
doaj   +1 more source

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

European Journal of Human Genetics, 2023
L. Beunk, M. Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne M Buunk, H. Guchelaar, E. Houwink, A. Risselada, G. Rongen, R. V. van Schaik, J. Swen, D. Touw, R. van Westrhenen, V. Deneer, J. van der Weide   +14 more
semanticscholar   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

UHPLC–MS/MS Method for the Simultaneous Quantification of 12 Antiretroviral Drugs in Human Plasma Using Dried Sample Spot Devices: Development, Validation, and Stability Evaluation

Pharmaceutics
Background/Objectives: In several contexts, Dried Sample Spot Devices (DSSDs) offer a convenient and safe alternative for sampling, storage, and shipment, allowing the transport and storage of biological samples at room temperature, reducing shipment ...
Sara Soloperto, Elisa Martina, Alice Palermiti, Elisa Barnini, Greta Sabbia, Gianluca Bianco, Martina Billi, Camilla Martino, Alessandra Manca, Marco Simiele, Jessica Cusato, Antonio D’Avolio, Amedeo De Nicolò   +12 more
doaj   +1 more source

Pharmacogenetics and personalized medicine

Saúde & Tecnologia, 2016
Pharmacogenetics aims to identify genetic differences between individuals that may influence the response to drug therapy, improving their effectiveness and safety. Associated with the pharmacogenetics emerges ‘personalized medicine’.
Miguel Brito
doaj   +1 more source